These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14621452)

  • 1. Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation.
    Rosas S; Szapary P; Rader DJ
    Cardiol Clin; 2003 Aug; 21(3):377-92. PubMed ID: 14621452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation.
    Rader DJ; Rosas S
    Med Clin North Am; 2000 Jan; 84(1):43-61. PubMed ID: 10685127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update: clinical lipidology].
    Parhofer KG
    MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
    Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J;
    Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update of lipid lowering therapy].
    Riesen WF; Mordasini RC
    Praxis (Bern 1994); 2008 Nov; 97(22):1179-84. PubMed ID: 18979436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients.
    Hanes DS; Nicholson PG; Raval DD; Hooper FL; Behrens MT; Weir MR
    Am J Ther; 1997; 4(2-3):85-91. PubMed ID: 10423597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
    Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
    Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperlipidemia of chronic renal failure.
    Kaysen GA
    Blood Purif; 1994; 12(1):60-7. PubMed ID: 7986478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic therapy of lipid disorders in the elderly.
    Aronow WS
    Am J Geriatr Cardiol; 2002; 11(4):247-56. PubMed ID: 12091773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy.
    Wiklund O; Pirazzi C; Romeo S
    Curr Cardiol Rep; 2013 Sep; 15(9):397. PubMed ID: 23888382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.
    Gomaraschi M; Adorni MP; Banach M; Bernini F; Franceschini G; Calabresi L
    Handb Exp Pharmacol; 2015; 224():593-615. PubMed ID: 25523003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study.
    Andersson C; Lyass A; Vasan RS; Massaro JM; D'Agostino RB; Robins SJ
    Am Heart J; 2014 Dec; 168(6):878-83.e1. PubMed ID: 25458651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
    Toth PP; Zarotsky V; Sullivan JM; Laitinen D
    Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.
    Ichimaru N; Takahara S; Kokado Y; Wang JD; Hatori M; Kameoka H; Inoue T; Okuyama A
    Atherosclerosis; 2001 Oct; 158(2):417-23. PubMed ID: 11583721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.